inclusion criteria: 1. adult patients (18 years) 2. must have a clinical diagnosis of sars-cov-2, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing 3. patients must not have received any antiviral treatments known to affect sars-cov-2 4. patients must agree that they are not permitted to use any other treatment to affect sars-cov-2 during a period of 6 months after undergoing sce therapy 5. adequate venous access for apheresis 6. ability to provide informed consent 7. for female patients only, willingness to use fda-recommended birth control (http://www.fda.gov/downloads/forconsumers/byaudience/forwomen/freepublications/ucm356451.pdf) until 6 months post treatment. 8. must agree to comply with all study requirements and be willing to complete all study visits

inclusion criteria: 1. adult patients (18 years) 2. must have a clinical diagnosis of sars-cov-2, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing 3. patients must not have received any antiviral treatments known to affect sars-cov-2 4. patients must agree that they are not permitted to use any other treatment to affect sars-cov-2 during a period of 6 months after undergoing sce therapy 5. adequate venous access for apheresis 6. ability to provide informed consent 7. for female patients only, willingness to use fda-recommended birth control (http://www.fda.gov/downloads/forconsumers/byaudience/forwomen/freepublications/ucm356451.pdf) until 6 months post treatment. 8. must agree to comply with all study requirements and be willing to complete all study visits

inclusion criteria: adult patients (18 years) must have a clinical diagnosis of sars-cov-2, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing patients must not have received any antiviral treatments known to affect sars-cov-2 patients must agree that they are not permitted to use any other treatment to affect sars-cov-2 during a period of 6 months after undergoing sce therapy adequate venous access for apheresis ability to provide informed consent for female patients only, willingness to use fda-recommended birth control (http://www.fda.gov/downloads/forconsumers/byaudience/forwomen/freepublications/ucm356451.pdf) until 6 months post treatment. must agree to comply with all study requirements and be willing to complete all study visits

inclusion criteria: adult patients (18 years) must have a clinical diagnosis of sars-cov-2, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing patients must not have received any antiviral treatments known to affect sars-cov-2 patients must agree that they are not permitted to use any other treatment to affect sars-cov-2 during a period of 6 months after undergoing sce therapy adequate venous access for apheresis ability to provide informed consent for female patients only, willingness to use fda-recommended birth control (http://www.fda.gov/downloads/forconsumers/byaudience/forwomen/freepublications/ucm356451.pdf) until 6 months post treatment. must agree to comply with all study requirements and be willing to complete all study visits

inclusion criteria: 1. adult patients (18 years) 2. must have a clinical diagnosis of sars-cov-2, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing 3. patients must not have received any antiviral treatments known to affect sars-cov-2 4. patients must agree that they are not permitted to use any other treatment to affect sars-cov-2 during a period of 6 months after undergoing sce therapy 5. adequate venous access for apheresis 6. ability to provide informed consent 7. for female patients only, willingness to use fda-recommended birth control (http://www.fda.gov/downloads/forconsumers/byaudience/forwomen/freepublications/ucm356 451.pdf) until 6 months post treatment. 8. must agree to comply with all study requirements and be willing to complete all study visits

inclusion criteria: 1. adult patients (18 years) 2. must have a clinical diagnosis of sars-cov-2, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing 3. patients must not have received any antiviral treatments known to affect sars-cov-2 4. patients must agree that they are not permitted to use any other treatment to affect sars-cov-2 during a period of 6 months after undergoing sce therapy 5. adequate venous access for apheresis 6. ability to provide informed consent 7. for female patients only, willingness to use fda-recommended birth control (http://www.fda.gov/downloads/forconsumers/byaudience/forwomen/freepublications/ucm356 451.pdf) until 6 months post treatment. 8. must agree to comply with all study requirements and be willing to complete all study visits